TY - JOUR
T1 - Implementing targeted therapies in the treatment of glioblastoma
T2 - Previous shortcomings, future promises, and a multimodal strategy recommendation
AU - Fougner, Vincent
AU - Hasselbalch, Benedikte
AU - Lassen, Ulrik
AU - Weischenfeldt, Joachim
AU - Poulsen, Hans Skovgaard
AU - Urup, Thomas
N1 - © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
PY - 2022/11/4
Y1 - 2022/11/4
N2 - The introduction of targeted therapies to the field of oncology has prolonged the survival of several tumor types. Despite extensive research and numerous trials, similar outcomes have unfortunately not been realized for glioblastoma. For more than 15 years, the standard treatment of glioblastoma has been unchanged. This review walks through the elements that have challenged the success of previous trials and highlight some future promises. Concurrently, this review describes how institutions, through a multimodal and comprehensive strategy with 4 essential components, may increase the probability of finding a meaningful role for targeted therapies in the treatment of glioblastoma. These components are (1) prudent trial designs, (2) considered drug and target selection, (3) harnessed real-world clinical and molecular evidence, and (4) incorporation of translational research.
AB - The introduction of targeted therapies to the field of oncology has prolonged the survival of several tumor types. Despite extensive research and numerous trials, similar outcomes have unfortunately not been realized for glioblastoma. For more than 15 years, the standard treatment of glioblastoma has been unchanged. This review walks through the elements that have challenged the success of previous trials and highlight some future promises. Concurrently, this review describes how institutions, through a multimodal and comprehensive strategy with 4 essential components, may increase the probability of finding a meaningful role for targeted therapies in the treatment of glioblastoma. These components are (1) prudent trial designs, (2) considered drug and target selection, (3) harnessed real-world clinical and molecular evidence, and (4) incorporation of translational research.
KW - glioblastoma
KW - real-world evidence
KW - targeted treatment
KW - translational research
KW - trial design
UR - http://www.scopus.com/inward/record.url?scp=85145418458&partnerID=8YFLogxK
U2 - 10.1093/noajnl/vdac157
DO - 10.1093/noajnl/vdac157
M3 - Review
C2 - 36325372
SN - 2632-2498
VL - 4
SP - 1
EP - 11
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
IS - 1
M1 - vdac157
ER -